Dragos Ciocan

Dr. Dragos Ciocan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
CHCamille Houron
Camille Houron
DCDragos Ciocan
Dragos Ciocan
TNTrainel Nicolas
Trainel Nicolas
FMFrançoise Mercier-Nomé
Françoise Mercier-Nomé
CHCindy Hugot
Cindy Hugot
ACAnne Marie Cassard-Doulcier
Anne Marie Cassard-Doulcier
Pectin, a soluble fiber, improves non-alcoholic fatty-liver disease (NAFLD), but its mechanisms are unclear. We aimed to investigate the role of pectin-induced changes in intestinal microbiota (IM) in NAFLD. We recovered the IM from mice fed a high-fat diet, treated or not with pectin, to perform a fecal microbiota transfer (FMT). Mice fed a high-fat diet, which induces NAFLD, were treated with pectin or received a fecal microbiota transfer (FMT) from mice treated with pectin before (preventive FMT) or after (curative FMT) being fed a high-fat diet. Pectin prevented the development of NAFLD, induced browning of adipose tissue, and modified the IM without increasing the abundance of proteobacteria. Preventive FMT also induced browning of white adipose tissue but did not improve liver steatosis, in contrast to curative FMT, which induced an improvement in steatosis. This was associated with an increase in the concentration of short-chain fatty acids (SCFAs), in contrast to preventive FMT, which induced an increase in the concentration of branched SCFAs. Overall, we show that the effect of pectin may be partially mediated by gut bacteria.

20 November 2024 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
WHWanchao Hu
Wanchao Hu
SNSabrine Naimi
Sabrine Naimi
NTNicolas Trainel
Nicolas Trainel
VMVanessa Liévin-Le Moal
Vanessa Liévin-Le Moal
GPGabriel Perlemuter
Gabriel Perlemuter
ACAnne Marie Cassard-Doulcier
Anne Marie Cassard-Doulcier
The intestinal microbiota (IM) plays a role in the severity of alcohol-associated liver disease. Modifying severe alcohol-associated hepatitis (AH) dysbiosis improves liver injury through tryptophan (Trp) metabolites and the aryl hydrocarbon receptor (AhR). However, Trp’s effect on the IM in alcohol use disorder (AUD) patients remains unclear. Here, we used an in vitro microbiota modeling system named Minibioreactor arrays (MBRAs). Feces from AUD patients with or without AH were treated with low, normal, or high Trp concentrations, with subsequent treatment with alcohol. Microbiota composition and AhR activity were studied. We showed that microbial communities from donors were maintained in MBRAs. High and low Trp increased the abundance of pathogen Escherichia Shigella. In the absence of alcohol, Trp changed more bacteria in AUD IM compared to AH IM. Normal Trp increased the AhR activity. Overall, maintaining normal Trp levels may prevent dysbiosis in AUD or AH, pending in vivo confirmation.

1 April 2020 in médecine/sciences
Verified
Journal Article
Open access
PDF file
DCDragos Ciocan
Dragos Ciocan
ACAnne Marie Cassard-Doulcier
Anne Marie Cassard-Doulcier
Médecine/sciences (M/S), revue internationale dans le domaine de la recherche biologique, médicale et en santé

1 April 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
DCDragos Ciocan
Dragos Ciocan
CVC.S. Voican
C.S. Voican
LWL. Wrzosek
L. Wrzosek
CHC. Hugot
C. Hugot
DRD. Rainteau
D. Rainteau
GPG. Perlemuter
G. Perlemuter